In other words, the price has increased by $0.0000 from its previous closing price. On the day, 5741735 shares were traded. CLOV stock price reached its highest trading level at $1.1600 during the session, while it also had its lowest trading level at $1.1050.
Our goal is to gain a better understanding of CLOV by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 0.91 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 27.67. For the most recent quarter (mrq), Quick Ratio is recorded 1.20 and its Current Ratio is at 1.20. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Cowen on February 02, 2022, Upgraded its rating to Market Perform and sets its target price to $3 from $7 previously.
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 06 when Loengard Anna U bought 11,000 shares for $1.30 per share. The transaction valued at 14,300 led to the insider holds 10,000 shares of the business.
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLOV now has a Market Capitalization of 547.89M and an Enterprise Value of 32.65M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.20 while its Price-to-Book (P/B) ratio in mrq is 1.64. Its current Enterprise Value per Revenue stands at 0.01 whereas that against EBITDA is -0.13.
Stock Price History:
Over the past 52 weeks, CLOV has reached a high of $2.45, while it has fallen to a 52-week low of $0.71. The 50-Day Moving Average of the stock is 1.2308, while the 200-Day Moving Average is calculated to be 1.0595.
The stock has traded on average 8.37M shares per day over the past 3-months and 4.12M shares per day over the last 10 days, according to various share statistics. A total of 479.16M shares are outstanding, with a floating share count of 366.89M. Insiders hold about 3.10% of the company’s shares, while institutions hold 32.50% stake in the company. Shares short for CLOV as of Aug 30, 2023 were 22.72M with a Short Ratio of 22.72M, compared to 21.7M on Jul 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 4.69% and a Short% of Float of 5.76%.
Its stock is currently analyzed by 5 different market analysts. On average, analysts expect EPS of -$0.12 for the current quarter, with a high estimate of -$0.09 and a low estimate of -$0.17, while EPS last year was -$0.16. The consensus estimate for the next quarter is -$0.16, with high estimates of -$0.11 and low estimates of -$0.2.
Analysts are recommending an EPS of between -$0.37 and -$0.58 for the fiscal current year, implying an average EPS of -$0.48. EPS for the following year is -$0.36, with 5 analysts recommending between -$0.14 and -$0.54.
5 analysts predict $482.23M in revenue for the current quarter. It ranges from a high estimate of $497.9M to a low estimate of $436.49M. As of the current estimate, Clover Health Investments Corp.’s year-ago sales were $856.82M, an estimated decrease of -43.70% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $482.24M, a decrease of -46.30% less than the figure of -$43.70% in the same quarter last year. There is a high estimate of $499M for the next quarter, whereas the lowest estimate is $443.87M.
A total of 6 analysts have provided revenue estimates for CLOV’s current fiscal year. The highest revenue estimate was $2.03B, while the lowest revenue estimate was $1.92B, resulting in an average revenue estimate of $2B. In the same quarter a year ago, actual revenue was $3.48B, down -42.40% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $2.06B in the next fiscal year. The high estimate is $2.09B and the low estimate is $2.02B. The average revenue growth estimate for next year is up 3.10% from the average revenue estimate for this year.